News

Cash generation was strong: adjusted free‑cash‑flow conversion exceeded 100 % for the quarter, with free cash flow of $0.5 billion and cash returned to shareholders totalling $2.41 billion, comprising $2.4 billion in share repurchases and dividend payouts. For full‑year 2026, management reiterated guidance of adjusted EPS $8.50–$8.70, organic sales...

Full article

First‑quarter 2026 results for 3M Company (MMM) posted revenue of $6.03 billion, a 1.3 % year‑over‑year rise, and adjusted earnings per share of $2.14, beating the consensus estimate of $1.98. Operating margin climbed to 23.2 %, up 30 basis points from the same period in 2025, while adjusted operating income reached $1.40 billion. The Safety and In...

Full article

Market reception to the rolling NDA announcement was muted, with BLTE’s stock closing at $165.23 on the day, a decline of 0.12%. This slight dip reflects typical market adjustment to developmental milestones. Nonetheless, the combination of regulatory designation, positive Phase 3 data, and significant capital raise positions Belite for a strategic...

Full article

Funding momentum follows the rolling submission. The company recently closed a $402 million underwritten public offering, earmarked for commercialization plans and pipeline expansion. Investor engagement is bolstered by a scheduled presentation at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on April 28 2026, wher...

Full article

In parallel, Belite has completed enrollment in a Phase 2/3 study of tinlarebant in adolescent STGD1 patients (DRAGON II) and launched a Phase 3 PHOENIX trial to evaluate efficacy in geographic atrophy associated with age‑related macular degeneration. These parallel trials aim to broaden tinlarebant’s therapeutic reach beyond STGD1.

Full article

Belite Bio Inc. (BLTE) has entered the second quarter of 2026 with a pivotal milestone: the initiation of a rolling New Drug Application (NDA) for tinlarebant, its lead oral therapy for Stargardt disease type 1 (STGD1). The rolling submission is slated for completion in Q2 2026, following the company’s Phase 3 DRAGON trial, which provided the prima...

Full article

Barry Callebaut AG’s interim results triggered an 18 % decline in the stock to CHF1,085, despite revenues and statutory earnings per share aligning with analyst estimates. Analysts responded by downgrading their consensus forecasts: the 2026 revenue outlook is now CHF13.0 billion, an 8.8 % drop from the previous year, and statutory EPS is projected...

Full article

In addition to DCF analysis, we also examine Soitec's Price‑to‑Sales (P/S) ratio, which is close to the wider Semiconductor industry average of 4.43x but below the peer group average of 6.59x. Our Fair Ratio for Soitec is 3.90x, suggesting that the company is trading at a higher multiple than implied by its earnings growth profile and industry comp...

Full article

Using a Discounted Cash Flow (DCF) analysis, we estimate Soitec's intrinsic value to be €16.15 per share, implying an overvaluation of 505.8% compared to its current price. Our model assumes cash flows will improve from a loss of €69.8 million in the latest twelve months to €25.4 million in 2026 and €58.2 million by 2029.

Full article

Soitec's stock price has surged 53.5% over 7 days and 293.3% year-to-date, raising concerns about its valuation. Our valuation model gives Soitec a score of 1 out of 6, indicating that the current share price of €97.82 may be overly optimistic. The company's recent growth has been fueled by increased interest in the semiconductor sector, but longer...

Full article